

## ***Retina Therapeutics***

### **Business Strategies**

The project aims to establish a company in the fields of biotechnology and medicine. The planned company will focus on the development and production of novel bioactive substances, specializing in the treatment of the hereditary retinal disease Morbus Best.

### **Core technologies and services**

Morbus Best is one of the rare eye diseases that usually occurs in childhood and adolescence and progresses slowly. As the eyesight is significantly impaired in both eyes over time, the chronic disease often leads to psychological stress and depression. There are currently no treatment options for this genetic disease. The working group led by Prof. Dr. Bernhard Weber from the Institute of Human Genetics at the University of Regensburg has been researching the causes of Morbus Best for over 25 years. Initially, this working group identified the disease-associated gene and established the causal link with the disease. Based on this discovery, a promising approach for the treatment of Morbus Best has recently been developed.